NeuroFlex Podcast

James O’Hara is a Nurse Practitioner with a passion for evidence-based, individualized medicine. He utilizes an integrative approach which combines lifestyle interventions, supplementation, and medications when indicated to empower patients to feel better and live longer, healthier lives.https://www.jamesoharanp.com

Courtney is licensed to practice law in California, Florida, and Texas. She practices at Feldman Legal Advisors PLLC, a cannabis and psychedelics business law firm based in New York State. Additionally, she serves as Policy Advisor for Decriminalize Nature, General Counsel for the Society for Psychedelic Outreach, Reform, and Education (SPORE), and Advisory Board Member of Heroic Hearts Project, Inc. She was a lead drafter of the nation’s first voter-initiated psilocybin policy reform ordinance in 2018, and has unparalleled experience drafting and helping to implement state and local policy reform measures relating to the decriminalization of psychedelics and the establishment of cannabis regulatory regimes (inclusive of hemp and marijuana).

Steven Feinberg, PhD. is a Neurostrategist, Executive Coach and High Performance Team builder for some of the sharpest, smartest brains and businesses in America. He works with CEO’s, senior executives and business founders, from billion-dollar Corporate 500s to young and hungry entrepreneurial start-ups, across brands like Oracle, Google, LinkedIn, Wells Fargo, Hitachi and Xero, ranked Number 1 innovation Start-up.

As a dynamic and socially-conscious entrepreneur, Patrick uses creativity and a passion for human connectivity to unite individuals across social and corporate spectrums. His superpower is making solid introductions that create meaningful outcomes and amplify impact. He’s currently President at Microdose Psychedelic Insights, developing the industry’s premier events and media platform alongside a highly motivated and engaged startup team. He’s spoken at the Concordia Annual Summit 2022 in New York, the first Medical Psychedelic House of Davos in Switzerland, Burning Man in Nevada, Wonderland Miami, and Plant Medicine Week in Malta. Having evolved from a successful career in photography and co-founding a few cannabis companies, Patrick’s focus is helping businesses achieve financial success while supporting nonprofits & charities in emerging industries. He currently sits on the board of directors for Heroic Hearts Project Canada, and advisory board for the Plant Medicine Coalition in support of their work.https://microdose.buzz

Dr. Jill Carnahan is Your Functional Medicine Expert® and author of Unexpected (March 2023), is the leading voice in mold and mold-related illness and often referred to as "The Sherlock Holmes of Medicine." In fact, she was recently featured in People Magazine for solving the medical mystery behind ABC's The Bachelorette's Ryan Sutter's years long battle with Lyme Disease. Dr. Jill is double board-certified in Family Medicine and Integrative Holistic Medicine and has sustained a 5+ year waiting list as the Medical Director of Flatiron Functional Medicine, a widely sought-after practice. She uses nutritional protocols and supplements, lifestyle changes, and medication to increase patient level of function and always seeks the gentlest and least invasive way to restore health and optimize healing. As a survivor of breast cancer, Crohn’s disease, and toxic mold illness, Dr. Jill brings a unique perspective to treating a variety of complex and chronic illness and has traveled the world sharing her knowledge of hope, health and healing live on stage as well as through newsletters, articles, books, podcasts, and social media.https://www.drjillhealth.com

Amanda Siebert is a Vancouver-based freelance journalist and author whose work has appeared in the New York Times, the Georgia Straight, VICE, and more. Her first book, The Little Book of Cannabis: How Marijuana Can Improve Your Life, was published in 2018 and she just released her newest book Psyched: Seven Cutting Edge Psychedelics Changing the World earlier this year.https://amandasiebert.com

Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company's board of directors. With over 30 years of executive management experience overall, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration.Algernon Pharmaceuticals plans to be the first Company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible this year. DMT is a "classic" psychedelic compound part of the tryptamine family.https://algernonpharmaceuticals.com

Born in the USA, Dallas McClain is a passionate reader of personal development books and a tennis enthusiast.He is the Chief Information Officer and Editor of Biohackers Update Magazine and the co-founder. He holds a bachelor’s degree in Biological Sciences, as well as a TEFL level 5 certificate in teaching English. He is currently living in Orlando, Florida with his wife and daughter where he enjoys writing, sports, and nature hikes in his free time.https://biohackersmagazine.com

Adam B. Coape-Arnold is the CEO and Founder of Cubed Biotech Inc. He has a decade of experience owning and operating premium brands in the regulated industries of raw dairy, yogurt, and cannabis, with over $50 million in sales to date. Cubed is a Montreal-based Canadian company that intends to develop & produce psychedelic medicine inspired by historical ethnobotany to disrupt the current treatments of mental illness & addiction. Cubed intends to cultivate, extract and also synthesize natural entheogens (Psilocybin from Mushrooms, Mescaline from Cacti, and Ayahuasca’s DMT & MAO-inhibitors), manufacture pharmaceutical mental-health & addiction medicines and develop its own proprietary compounds through clinical trials for pharmaceutical-grade distribution and commercialization.https://cubed3biotech.com

Dr. Roger McIntyre is the chairman and chief executive officer of Braxia Scientific. Dr. McIntyre is the world’s top-ranked depression researcher and has almost 25 years of providing care and conducting research, along with drug discovery and development, for persons with depression and related disorders.He is currently also a professor of psychiatry and pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada.https://braxiascientific.comhttps://psychiatry.utoronto.ca/faculty/roger-mcintyrehttps://www.linkedin.com/in/roger-mcintyre-976bb167?originalSubdomain=ca